Summary of Clinical Trials with Zafirlukast
- 1 June 1998
- journal article
- review article
- Published by American Thoracic Society in American Journal of Respiratory and Critical Care Medicine
- Vol. 157 (6) , S238-S246
- https://doi.org/10.1164/ajrccm.157.6.mar6
Abstract
Zafirlukast is an orally active and selective cysteinyl leukotriene (cysLT) receptor antagonist. In humans, zafirlukast antagonized the effects of exogenously administered LTD4 and cysLTs released endogenously in response to physical and chemical stimuli. Zafirlukast antagonized LTD4-induced bronchoconstriction, with effects still evident 12 h after drug administration. In clinical models of asthma, zafirlukast inhibited bronchospasm after allergen or exercise challenge in patients with asthma. In multicenter trials in patients with chronic, stable asthma, zafirlukast reduced asthma symptoms, decreased as-needed β -agonist use, and improved pulmonary function without increasing the number of adverse events. Zafirlukast also exhibited evidence of an anti-inflammatory effect in the lung in preliminary studies involving segmental antigen challenge. The results from these clinical trials demonstrate that zafirlukast is effective and safe for the prophylactic treatment of asthma. Calhoun WJ. Summary of clinical trials with zafirlukast.Keywords
This publication has 14 references indexed in Scilit:
- Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter studyClinical Therapeutics, 1997
- The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmaticsEuropean Respiratory Journal, 1994
- Inhaled ICI 204,219 Blocks Antigen-Induced Bronchoconstriction in Subjects With Bronchial AsthmaChest, 1994
- Potent Leukotriene D4Receptor Antagonist ICI 204/219 Given by the Inhaled Route Inhibits the Early but not the Late Phase of Allergen-induced BronchoconstrictionAmerican Review of Respiratory Disease, 1993
- The Protective Effect of Inhaled Leukotriene D4Receptor Antagonist ICI 204,219 against Exercise-induced AsthmaAmerican Review of Respiratory Disease, 1993
- Inhibition of Platelet-activating Factor-induced Bronchoconstriction by the Leukotriene D4Receptor Antagonist ICI 204,219American Review of Respiratory Disease, 1993
- Effect of the oral leukotriene antagonist, ICI 204,219, on antigen-induced bronchoconstriction in subjects with asthmaJournal of Allergy and Clinical Immunology, 1992
- Role of Leukotrienes in Exercise-induced Asthma: Inhibitory Effect of ICI 204219, a Potent Leukotriene D4Receptor AntagonistAmerican Review of Respiratory Disease, 1992
- Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjectsThe Lancet, 1991
- Inhibition of Leukotriene D4-induced Bronchoconstriction in Normal Subjects by the Oral LTD4Receptor Antagonist ICI 204,219American Review of Respiratory Disease, 1990